Publication | Closed Access

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

AsthmaRheumatologyPlacebo-controlled Phase 3ImmunologyClinical TrialsPharmacotherapyEosinophilic AsthmaEosinophilic DisorderImmunotherapyMedicineClinical AllergyAdd-on Treatment